Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 4/20 | 0.47 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | SLC16A3 | O15427 | 11/20 | 0.40 |
| ▸ | MCTS1 | Q9ULC4 | 8/20 | 0.38 |
| ▸ | SLC16A1 | P53985 | 8/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.36 |
| ▸ | HTR6 | P50406 | 2/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534366 | 0.88 | SLC16A3 (0.38) | SLC16A3MCTS1SLC16A1 | |
| SCHEMBL3528148 | 0.88 | PPARG (0.48) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3530329 | 0.87 | MAPT (0.43) | SLC16A3SLC16A1KDM4EALDH1A1HTR6 | |
| SCHEMBL3530590 | 0.82 | PPARG (0.39) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3530092 | 0.82 | PPARG (0.50) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3530102 | 0.82 | PPARG (0.63) | PPARGPPARAKDM4EALDH1A1NR1I2 | |
| SCHEMBL3531617 | 0.80 | PPARG (0.48) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3533511 | 0.80 | NOD1 (0.41) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3532413 | 0.80 | PPARG (0.41) | PPARGPPARASLC16A3MCTS1SLC16A1 | |
| SCHEMBL3530970 | 0.80 | PPARG (0.72) | PPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7728002-B2 | Use of pyrrolopyridine compounds for activating PPAR receptors and treatment of conditions involving such receptors | LABORATOIRES FOURNIER S.A. (FR) | 2010-06-01 | — | — | US | disclosed |
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | LABORATOIRES FOURNIER S.A. (FR) | 2009-09-24 | — | — | US | disclosed |
| US-7557122-B2 | Pyrrolopyridine compounds, method of making them and uses thereof | LABORATOIRES FOURNIER S.A. (FR) | 2009-07-07 | — | — | US | disclosed |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LABORATOIRES FOURNIER S.A. (FR) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239856-A1 | Use of Pyrrolopyridine Compounds for Activating PPAR Receptors and Treatment of Conditions Involving Such Receptors | PPARD, PPARA, PPARG | PPARG 3/4885PPARA 2/4885SLC16A3 2283/4885 |
| US-20080200495-A1 | Pyrrolopyridine Compounds, Method of Making Them and Uses Thereof | LIPG, PCSK9, PNLIP | PPARG 335/4885PPARA 168/4885SLC16A3 2244/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.